Holen Sie sich die Stockscreener-App
2.57
6.55%
-0.18
Handel nachbörslich:
2.59
0.02
+0.78%
Schlusskurs vom Vortag:
$2.75
Offen:
$2.72
24-Stunden-Volumen:
2.57M
Relative Volume:
0.71
Marktkapitalisierung:
$247.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.5482
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
-19.18%
1M Leistung:
+19.53%
6M Leistung:
+64.74%
1J Leistung:
+9.83%
1-Tages-Spanne:
$2.54
$2.8088
1-Wochen-Bereich:
$2.54
$3.20
52-Wochen-Spanne:
$0.9857
$3.67
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.57 | 264.73M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan - Investing.com Nigeria
Cabaletta Bio: Do You Buy With The Insiders? (NASDAQ:CABA) - Seeking Alpha
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Largest borrow rate increases among liquid names - TipRanks
Assessing Cabaletta Bio (CABA) Valuation After Insider Buying And FDA Clearance For Automated CAR T Manufacturing - Yahoo Finance
Stock Analysis: Does Cabaletta Bio Inc have pricing powerWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Strategic Partnerships Propel Cabaletta Bio Forward - StocksToTrade
Cabaletta Bio Unveils Strategic Plans Amid Price Target Revision - timothysykes.com
Cabaletta Bio Aims High with Strategic Initiatives for 2026 - StocksToTrade
Steven Nichtberger Bought 3.3% More Shares In Cabaletta Bio - Sahm
Returns Recap: Is Cabaletta Bio Inc stock trending bullishGap Down & Community Verified Trade Signals - baoquankhu1.vn
Cabaletta Bio Unveils Strategic Plans Amid Financial Forecast Changes - StocksToTrade
Cabaletta Bio Stock (CABA) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative
Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates - MSN
Cabaletta Bio Advances Rese-cel Toward Pivotal Milestones, Expands Autoimmune Cell Therapy Pipeline - RTTNews
Why Cabaletta Bio (CABA) Is Up 41.3% After FDA Clears Automated CAR T Manufacturing Platforms - Yahoo Finance
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
Cabaletta Bio Sees Unusually Large Options Volume (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (CABA) Shares Surge 11% After Insider Buying - GuruFocus
Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape - TechStock²
Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners may be pleased with recent gains after 9.7% loss over the past year - simplywall.st
Simon Mark, Cabaletta bio director, buys $25,261 in shares By Investing.com - Investing.com UK
Cabaletta Bio (CABA) CEO Nichtberger buys $100,777 in shares By Investing.com - Investing.com UK
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq
Cabaletta Bio Insiders Go on a Buying Spree, Signaling Strong Confidence From the Top - TipRanks
Insider Buying: Michael Gerard Acquires Shares of Cabaletta Bio Inc (CABA) - GuruFocus
Insider Buying: Steve Gavel Acquires Shares of Cabaletta Bio Inc (CABA) - GuruFocus
Steven Nichtberger Acquires 45,000 Shares of Cabaletta Bio (NASDAQ:CABA) Stock - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Director Mark Simon Acquires 11,061 Shares - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Insider Gwendolyn Binder Buys 11,312 Shares - MarketBeat
Insider Buying: Cabaletta Bio (NASDAQ:CABA) Insider Acquires 8,800 Shares of Stock - MarketBeat
Michael Gerard Purchases 6,600 Shares of Cabaletta Bio (NASDAQ:CABA) Stock - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Director Shawn Tomasello Acquires 22,725 Shares - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Insider Acquires 22,170 Shares - MarketBeat
Gerard, Cabaletta bio general counsel, buys $14.9k in CABA By Investing.com - Investing.com Australia
Cabaletta Bio (CABA) CEO Nichtberger buys $100,777 in shares - Investing.com
Simon Mark, Cabaletta bio director, buys $25,261 in shares - Investing.com
Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates - mychesco.com
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year - BioSpace
Guidance Update: Is Cabaletta Bio Incs ROIC above industry averageJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Portfolio Recap: Can Cabaletta Bio Inc disrupt its industryOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
Is Cabaletta Bio Incs ROIC above industry averageMarket Growth Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Cabaletta Bio stock rating reiterated by Cantor Fitzgerald on IND clearance By Investing.com - Investing.com South Africa
Cabaletta Bio stock rating reiterated by Cantor Fitzgerald on IND clearance - Investing.com South Africa
CABA Initiates Key Trials and Advances Manufacturing for Rese-Ce - GuruFocus
Cabaletta Bio Sets 2026 Strategy for Rese-cel Expansion - TipRanks
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):